196 related articles for article (PubMed ID: 35724767)
21. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.
Vido MJ; Le K; Hartsough EJ; Aplin AE
Cell Rep; 2018 Nov; 25(6):1501-1510.e3. PubMed ID: 30404005
[TBL] [Abstract][Full Text] [Related]
22. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
[TBL] [Abstract][Full Text] [Related]
23. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
Nakai C; Mimaki S; Matsushima K; Shinozaki E; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Suzuki Y; Akagi K; Nomura S; Fujii S; Sugiyama M; Nishida N; Mizokami M; Koh Y; Koshizaka T; Okada H; Abe Y; Ohtsu A; Yoshino T; Tsuchihara K
Int J Clin Oncol; 2023 May; 28(5):654-663. PubMed ID: 36856908
[TBL] [Abstract][Full Text] [Related]
24. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
25. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
26. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
Coffee EM; Faber AC; Roper J; Sinnamon MJ; Goel G; Keung L; Wang WV; Vecchione L; de Vriendt V; Weinstein BJ; Bronson RT; Tejpar S; Xavier RJ; Engelman JA; Martin ES; Hung KE
Clin Cancer Res; 2013 May; 19(10):2688-98. PubMed ID: 23549875
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
28. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
29. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
30. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
32. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
33. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
34. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
35. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
36. Combined BRAF, EGFR, and MEK Inhibition in Patients with
Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
38. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
39. Improvements in Clinical Outcomes for
Morris VK; Bekaii-Saab T
Clin Cancer Res; 2020 Sep; 26(17):4435-4441. PubMed ID: 32253230
[TBL] [Abstract][Full Text] [Related]
40. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
